The renown medical research experts are anxious to get some innovative new drugs approved, including Januvia, an oral diabetes drug. On Saturday, Merck will present key phase III data regarding Januvia to experts attending a diabetic medical conference.

Merck tanked big time last year after being faced with multi-million dollar law suits after their drug, Vioxx, was linked to several fatalities. The company hopes that Januvia will put them back on the map, and back in the bank.

Of course, we can only hope that Merck will consider more than just recouping lost money, and not rush a lackluster drug onto the market. This seems a concern as the company is rushing to beat a Swiss company's version of an oral diabetes drug,
Galvus, which would provide stiff competition.

Let's hope they mix in caution with the enthusiasm. After the Vioxx fiasco, would you feel comfortable trying a diabetic drug created by the same people?